"Rising Healthcare Costs: Diabetes Takes the Lead as America's Costliest Chronic Condition"
Diabetes is projected to become the most expensive chronic condition in America, with a potential 700% increase in type 2 diabetes cases among people under 20 by 2060. The rising popularity of GLP-1 receptor agonists (GLP-1s) like Ozempic has contributed to the increasing costs of diabetes treatment. However, it is important to recognize that GLP-1s are not a cure-all and lifestyle changes remain crucial for effective diabetes management. Better Therapeutics has developed a smartphone-based cognitive behavioral therapy (CBT) software called AspyreRx to address the behavioral and lifestyle-related root causes of diabetes. Clinical trials have shown that adding AspyreRx to GLP-1 treatment resulted in significant improvements in clinical outcomes, including reduced HbA1c levels and weight loss. Prescription digital therapeutics like AspyreRx have the potential to enhance access to healthcare and mitigate health disparities.